And platinum medicine whole human source CD73 antibody preclinical data disclosure.

Guide: And Platinum Pharma presents all-human CD73 antibody preclinical data at AACR 2020 and Platinum Pharmaceuticals announced yesterday that it will present the preclinical data of the whole human source CD73 antibody (HBM1007) with electronic posters at the American Society for Cancer Research (AACR) Online Annual Meeting II, June 22-24, 2020.
HBM1007 is an all-human monoclonal antibody for CD73, an extracellular nucleotide enzyme expressed on matrix cells and tumors that converts extracellular monophosphate adenosine (AMP) into adenosine.
high concentrations of adenosine mainly transmit signals through A2A receptors, which inhibit the response of congenital and adaptive immune cells, causing tumors to escape the surveillance of the immune system.
HBM1007 identifies the unique epithelial of CD73 and acts with cancer through a dual mechanism: first, it blocks the enzyme activity of cell membranes and soluble CD73, independent of the concentration of the substrate AMP, thus maintaining activity in the tumor microenvironment;
, HBM1007 can significantly reduce the activity of CD73 enzyme syntledating, as well as the function of non-enzyme activity mediated.
.